Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ambalalrabhai EnterprisesBOM:500009 -0.67%65 Days Payable is 93.10 as of Mar. 2026, which is 36% below its 10-year median of 146.33. GuruFocus rates BOM:500009 with a GF Score™ of 65/100 and a GF Value™ of ₹41.76 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 926 Drug Manufacturers companies, Ambalalrabhai Enterprises ranks better than 67.6% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ambalalrabhai Enterprises's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambalalrabhai Enterprises Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ambalalrabhai Enterprises's Days Payable distribution charts can be found below:
* The bar in red indicates where Ambalalrabhai Enterprises's Days Payable falls into.
Ambalalrabhai Enterprises Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ambalalrabhai Enterprises's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambalalrabhai Enterprises (BOM:500009) has a Days Payable of 93.10 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ambalalrabhai Enterprises and its competitors. This is 36% below median its historical median of 146.33. Over the past decade, Ambalalrabhai Enterprises' Days Payable has ranged from 123.40 to 192.42. According to the industry distribution chart, Ambalalrabhai Enterprises ranks #300 out of 926 companies in the Drug Manufacturers industry, placing it in the top 32.4%.
Is Ambalalrabhai Enterprises' Days Payable too high?
Ambalalrabhai Enterprises' current Days Payable of 93.10 is 36% below median its 10-year median of 146.33. Over the past 10 years, this metric has ranged from a low of 123.40 to a high of 192.42. The Drug Manufacturers industry median Days Payable is 90.22. Ambalalrabhai Enterprises' value of 93.10 is 3.2% above this industry median. Based on the distribution chart, Ambalalrabhai Enterprises ranks #300 out of 926 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ambalalrabhai Enterprises has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ambalalrabhai Enterprises' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ambalalrabhai Enterprises ranks #300 out of 926 companies for Days Payable. This puts Ambalalrabhai Enterprises in the upper half of its industry. The industry median Days Payable is 90.22. Ambalalrabhai Enterprises' value of 93.10 is 3.2% above this benchmark. Historically, Ambalalrabhai Enterprises' own Days Payable has ranged from 123.40 to 192.42 over the past decade. While the company's 10-year median is 146.33 vs. the industry median of 90.22, Ambalalrabhai Enterprises has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ambalalrabhai Enterprises's current Days Payable of 93.10 is 3.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ambalalrabhai Enterprises and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambalalrabhai Enterprises's current Days Payable is 93.10, which is 36% below median its own 10-year median of 146.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambalalrabhai Enterprises stock overvalued right now?
Based on GuruFocus' analysis, Ambalalrabhai Enterprises (BOM:500009) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹41.76, compared to a current price of ₹32.45 — trading 22.3% below its estimated fair value. The current Days Payable is 93.10, which is 36% below median its 10-year median of 146.33 and 3.2% above the Drug Manufacturers industry median of 90.22. Ambalalrabhai Enterprises' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ambalalrabhai Enterprises (BOM:500009), the current Days Payable is 93.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambalalrabhai Enterprises (BOM:500009) Overvalued in 2026?
Based on GuruFocus' analysis, Ambalalrabhai Enterprises stock appears to be undervalued.
The current stock price of ₹32.45 is trading 22.3% below its estimated GF Value™ of ₹41.76.
GuruFocus considers Ambalalrabhai Enterprises to be Modestly Undervalued.
Key valuation signals for BOM:500009:
Days Payable: 93.10 (36% below median its 10-year median of 146.33)
GF Value™: ₹41.76 vs. price of ₹32.45 (22.3% below fair value)
Industry Position: 3.2% above the Drug Manufacturers median (#300 of 926)
No single metric tells the full story. See the BOM:500009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambalal Sarabhai Enterprises Ltd is an India-based company engaged in the manufacturing and marketing of Drugs and Formulation. The operating segment of the company is Pharmaceutical Products. It serves domestic as well as International markets.
65GF Score
Get the complete analysis for BOM:500009
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500009 has been successfully added to your 
